Why the study?
Emerging evidence implicates microRNAs in the etiology and progression of Takotsubo Syndrome, but their regulatory networks had not been systematically explored.
What is the role of circulating and tissue-specific microRNAs in the pathophysiological mechanisms, diagnosis, and potential treatment of Takotsubo Syndrome?
What is the role of circulating and tissue-specific microRNAs in the pathophysiological mechanisms, diagnosis, and potential treatment of Takotsubo Syndrome?
Answers are grounded in this paper and cite their sources.
This systematic review synthesizes evidence from 14 studies demonstrating that specific microRNAs (such as miR-16, miR-26a, miR-371a-5p, and miR-204) regulate key pathophysiological pathways in Takotsubo Syndrome and hold promise as diagnostic biomarkers to differentiate it from acute myocardial infarction.
MicroRNAs (miRNAs) have emerged as crucial regulators of gene expression and have been implicated in various physiological and pathological processes, including cardiovascular diseases. The clinical presentation, diagnostic criteria, and proposed pathophysiological mechanisms of Takotsubo Syndrome (TTS) are discussed, with an emphasis on the emerging evidence implicating miRNAs in its etiology and progression. A systematic review following the PRISMA guidelines was performed on the evidence regarding the interplay between miRNAs and TTS. A search of the Pubmed, Web of Science, and Scopus databases was conducted and resulted in 584 articles. Of these, 14 full-text articles were eligible for inclusion in the qualitative analysis. The reviewed studies suggest that multiple miRNAs are involved in the processes associated with TTS pathophysiology, including acute and chronic myocardial inflammation, oxidative stress, apoptosis, microvascular dysfunction, hypertrophy, and, ultimately, maladaptive cardiac remodelling. This review provides an overview of the current understanding of miRNAs in cardiovascular pathophysiology, with a specific focus on their potential roles in TTS. To the best of our knowledge, this is the first systematic exploration of the miRNAs involved in TTS and its modulation as potential biomarkers or therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: